Purpose: This study aimed to develop hypotheses to explain the increasing tramadol utilisation, evaluate the impact of tramadol classification, and explore the trend between tramadol utilisation and related deaths in the United Kingdom.
| INTRODUCTION
Tramadol is indicated for moderate to severe pain in the United Kingdom (UK). In the past decade, the utilisation of tramadol has consistently increased in many countries, including the United States (US), Germany, 1 and the UK. 2 According to the UK National Health Service (NHS) Business Services Authority, the annual tramadol utilisation in England increased from 5.9 to 11.1 million defined daily doses (DDDs) 2 between 2005 and 2012; coincidently, there was a marked increase in the number of tramadol-related deaths during the same period.
In the US, prolonged opioid use for persistent pain has been identified as the main reason for increasing opioid utilisation, 3 although several clinical guidelines [4] [5] [6] suggest the long-term opioid use for chronic noncancer pain (CNCP) remains controversial. 7, 8 However, the reasons attributable to the increasing opioid utilisation, such as tramadol, have not been investigated in the UK.
Currently, there is no direct evidence to infer the relationship between increasing tramadol utilisation and related mortality in the UK. At the population level, the NHS Business Services Authority only presented tramadol utilisation without adjusting for population size, and tramadol utilisation in Wales was not included in the report, 2 but the published mortality figures from the Office for National Statistics covered both England and Wales. 9 Consequently, the correlation between tramadol utilisation and tramadol-related deaths has not been established. 2 Because of the concerns about safety and potential risk of misuse, tramadol was classified as a Schedule 3 controlled substance in June 2014 in the U.K. 2 Thereafter, tramadol prescribing needs to follow stricter prescription requirements with clear defined dose and the maximum supply days should not exceed 30 days. 2 For such a medicine with high usage and potential harm, the effectiveness of policy intervention on utilisation and tramadol-related mortality is an important public health issue. However, the effect of tramadol classification has not been explored.
Therefore, this study aimed to develop hypotheses to explain the increasing tramadol utilisation and evaluate policy changes in the UK.
The objectives were to (1) identify potential reasons for increasing tramadol utilisation from individual utilisation patterns; (2) evaluate the impact of tramadol classification on prevalence of tramadol users and tramadol utilisation; and (3) explore the trend between tramadol utilisation and tramadol-related deaths.
2 | METHODS
| Study design and data source
This cross-sectional study used several data sources that cover information from different geographical regions and time frames, including aggregated-level and publically available data from the UK government sources as well as individual patient data (IPD) from a UK primary care database to address multiple research questions and compensate limitation of each database (Table 1) . 
| Outcomes measured using aggregated-level data
The annual number of tramadol-related deaths/100 000 inhabitants and annual and monthly number of DDDs of dispensed tramadol/ 1000 inhabitants were measured in aggregated-level statistics and datasets. The number of tramadol-related deaths was directly extracted from government reports. 9 The annual quantity of tramadol preparations reported in the PCA was used to calculate the annual number of DDDs dispensed in England 11 and Wales, 12 while the quantity of tramadol preparations extracted from monthly practice-level dispensing data was used to calculate the monthly number of DDDs dispensed in England. 13 The annual number of tramadol-related deaths was divided by the mid-year number of population in England and Wales and then
KEY POINTS
• The marked increase of tramadol utilisation in the UK primary care setting from 2000 to 2015 was influenced most by increasing prevalence, mean daily dose, and supply days for existing tramadol users.
• The level and trend of monthly prevalence of tramadol users and tramadol utilisation reduced after the classification of tramadol in June 2014.
• 
| Outcomes measured using IPD
The monthly prevalence and incidence of tramadol users/10 000 registrants, monthly DDDs/1000 registrants and annual supply days, and mean daily dose for each tramadol user were measured by using tramadol prescription records form CPRD.
Adult patients who received their first tramadol prescription during the study period were identified as new tramadol users in that calendar year, and if the patients received tramadol in the subsequence years, they were classified as existing users in the subsequence years.
The number of new and existing tramadol users was calculated in each calendar month and adjusted by the total number of active patients in the CPRD to derive the monthly incidence and prevalence of tramadol users/10 000 registrants.
The total dose of each tramadol prescription was calculated by multiplying strength and quantity and then converted to the monthly number of DDDs, which was further adjusted by the number of active patients in the particular calendar month to calculate the monthly number of DDDs of tramadol/1000 registrants.
For each tramadol prescription, the dose was divided by the numerical daily dose (recorded by physicians and available in the CPRD therapy file) to derive the number of supply days. If the interval between 2 consecutive prescriptions was shorter than the supply day of the anterior prescription, then the supply day was replaced by interval between the 2 prescriptions.
For each patient, the total doses of tramadol prescriptions and annual number of supply days were summed in each calendar year. If the annual number of supply days was more than 365 days, then it was capped to 365 days. The annual dose was divided by the annual number of supply days to derive the annual mean daily dose in particular calendar year.
| Data analysis
Descriptive statistics were used to report annual dose and number of supply days. The trend of (1) The Durbin Watson test was used to test first-order autocorrelation in each time series. As no first-order autocorrelation was found, 21 autoregressive integrated moving-average model was not applied in the ITSA. 22 In the regimented regression model, baseline trend before classification (β 1 ), change in the level (β 2 ), and change in trend after classification (β 3 ) were tested and reported for each time series.
Additional time points in the policy development were tested in sensitivity analysis (Appendix S1 
| Impact of tramadol classification on monthly tramadol utilisation
Tramadol classification had similar impacts on its utilisation in the results of ITSA using aggregated-level data and IPD. In the monthly practice-level dispensing data, the ITSA revealed that the level (β 2 : −12.9, P = .017) and the trend (β 3 : −1.6, P = .002) of monthly tramadol utilisation significantly decreased after tramadol classification, despite a significant increase in the baseline trend (β 1 : 0.79, P < .001) before tramadol classification (Figure 3) . Similarly, the IPD from CPRD showed a significant increase trend (β 1 : 0.56, P < .001) before tramadol classification, and the level significantly reduced at the launch of classification (β 2 : −16.3, P = .021), but there was no significant change in the trend of tramadol utilisation after classification.
When stratifying monthly tramadol utilisation into existing and new tramadol users, before the classification, the trend significantly increased in existing users (β 1 : 0.63, P < .001) (Figure 4 ) but decreased in new users (β 1 : −0.07, P < .001) ( Figure 5 ). After the launch of tramadol classification, the level significantly decreased in both existing users (β 2 : −13.8, P = .041) and new users (β 2 : −2.6, P < .001). However, there was no significant change in the trend of tramadol utilisation for both existing and new users after tramadol classification.
| Impact of tramadol classification on monthly prevalence and incidence of tramadol users
In addition to monthly tramadol utilisation, tramadol classification also decreased the prevalence of tramadol users. In the IPD from CPRD, the baseline trend significantly increased in prevalence (β 1 : 0.21, −0.37, P = .028), and there was no significant change in the trend of incidence ( Figure 1 ). All sensitivity analysis models found that other intervention time points had no significant effect on tramadol utilisation, prevalence, and incidence. 3 4 5 6 7 8 9 101112 1 2 3 4 5 6 7 8 9 101112 1 2 3 4 5 6 7 8 9 101112 1 2 3 4 5 6 7 8 9 101112 1 2 3 4 5 6 7 8 From the IPD, the monthly incidence of tramadol users doubled and the monthly prevalence increased fourfold. The mean daily dose of tramadol prescriptions increased, and more than 70% of tramadol users were existing users who had greater number of supply days than new users. Therefore, the increasing prevalence and incidence of tramadol users, higher mean daily dose, and the prolonged use of tramadol were the main causes of increasing tramadol utilisation over time. The increasing tramadol utilisation may be attributed to long-term opioid utilisation, which has been commonly observed in patients with CNCP. 3 In the UK, higher doses and prolonged use of strong opioids were related to increasing demands for pain relief in CNCP. 24 In addition, a cross-sectional study conducted in Germany found that higher tramadol utilisation was associated with CNCP diagnosis. 1 However, similar to other opioids, there is currently no robust evidence to support the clinical effectiveness of prolonged tramadol utilisation for CNCP. [25] [26] [27] [28] Moreover, evidence from post-mortem toxicological analysis in the UK suggests that tramadol-related deaths were more related to persistent tramadol users. [29] [30] [31] Nevertheless, the ITSA found that tramadol classification did not change the increasing trend of tramadol utilisation in existing tramadol users who had greater number of supply days. In addition, the proportion of tramadol-related deaths in all opioid-related deaths (10.5%) was still higher than codeine-related deaths (6.4%) in 2015, despite more prescriptions for codeine being dispensed. This is the first study to identify the influence of tramadol classification on its utilisation in the UK. To fully explore tramadol utilisation in the past 15 years, several national statistics and datasets as well as CPRD were used to compensate the limitations of each database.
We used DDDs to quantify tramadol utilisation that is easy to compare with previous studies and understand the clinical implication as it can be converted into oral morphine equivalent dose by multiplying the potency ratio. 37 Furthermore, to establish hypotheses for further analysis, potential reasons of increasing tramadol utilisation and tramadol-related deaths were identified by measuring both individual and population utilisation.
There are some limitations to this research. The CPRD does not include prescription records from secondary care and hence may underestimate tramadol utilisation, especially for acute tramadol use.
Tramadol prescriptions outside the study period were not included, and hence, the new users might be overestimated. Furthermore, this cross-sectional study aimed to establish potential hypotheses for changes in tramadol utilisation and deaths, but it was not intended to study the causal relationship between particular utilisation patterns such as chronic use and changes in tramadol utilisation. The number of tramadol-related deaths was an aggregated summary retrieved from government reports, and hence, characteristics of tramadol-related fatalities were not available.
In conclusion, the prolonged use by existing tramadol users and the increasing prevalence of tramadol users led to increasing tramadol utilisation over the past 15 years in the UK. Although tramadol classification altered tramadol utilisation and associated deaths, to optimise the use of tramadol in patients with CNCP, future studies are needed to identify the causal relationship between patient characteristics, long-term tramadol utilisation, and tramadol-related deaths.
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